Background. Because changes in antiretroviral therapy in resource-limited settings (RLSs) are delayed until patients experience immunological or clinical failure, it is important to be able to estimate the consequences in terms of accumulation of thymidine analogue (TA) mutations (TAMs).
. Virtual patient contributing 2 genotypic resistance test (GRT) pairs while receiving zidovudine (ZDV)-based failing regimens. ddI, didanosine; FTC, emtricitabine; LPV/r, ritonavir-boosted lopinavir; NVP, nevirapine; TDF, tenofovir; 3TC, lamivudine; VL, viral load.
ie, nevirapine or efavirenz) [1] . This recommendation is based on available evidence, clinical experience, and programmatic feasibility for wider introduction of antiretroviral therapy (ART) in RLSs [2] . These same guidelines also suggest that because human immunodeficiency virus (HIV) RNA monitoring is generally not available, the first ART regimen should be switched when patients experience immunological or clinical failure [1] . With a such a strategy, a substantial number of patients are likely to receive a virologically failing TA-containing regimen for extended periods of time.
Little is known about the possible long-term consequences of this strategy in terms of accumulation of resistance to TA mutations (TAMs) and their potential impact on response to second-line regimens. In a recent analysis, an appreciable percentage of patients accumulated drug resistance or required second-line treatment relatively soon after the start of first-line ART with stavudine, lamivudine, and nevirapine [3] . Similar studies of patients receiving first-line ART in Africa and Thailand showed a high rate of TAM accumulation in patients with immunological or clinical failure in response to WHO-recommended treatments [4] [5] [6] [7] [8] [9] [10] [11] . A slower accumulation rate for TAMs than for protease inhibitor (PI) mutations was observed in a Western cohort of patients treated with TA-PI combinations [12] . Mathematical modeling has been employed to try to estimate the rate of accumulation of resistance after the start of ART in ART-naive patients [13] . However, we know of no direct estimates as to how fast TAMs may accumulate during virological failure in patients receiving TA-containing regimens and no studies identifying predictors of TAM accumulation.
METHODS

Patients.
We studied patients in the EuroSIDA study who experienced virological failure while receiving a TA-containing regimen (virological failure defined as the first viral load of 1500 copies/mL after taking the same TA for у6 months) and who had у2 available genotypic resistance tests (GRTs) with a viral load of 1500 copies/mL at both GRTs and at any viral load measures between pairs of GRTs. We also required that both GRTs in a pair were obtained while the patient was receiving a TA-containing regimen. Because one of the objectives prompted by previous observations [14, 15] was to compare the rate of TAM accumulation for zidovudine with that observed for stavudine, patients had to be receiving exactly the same TA at the time of the first (t0) and second (t1) tests in a pair; all other drugs could be different at the 2 time points. Figure 1 illustrates a virtual patient who continued to receive a zidovudine-containing regimen. Furthermore, to be sure that patients had experienced failure with resistance, we included only those harboring a virus predicted by the Rega interpretation system (IS) to have reduced susceptibility to у1 drug received at the first GRT; version 7.1 for the drugs currently in use in clinical practice and version 6.4.1 for the remaining drugs (eg, nonboosted PIs) were used to predict the number of active drugs in the ART regimen at the time of the first GRT in a pair (t0) [16] . The time of the first GRT in a pair for an individual patient was defined as baseline-t0.
Genotyping. HIV-1 protease and reverse-transcriptase coding regions were genotyped in our central virology laboratory in Badalona, Spain, using the TRUGENE HIV-1 Genotyping Kit and OpenGene DNA Sequencing System, version 11.0 (Siemens Medical Solutions Diagnostics); most genotypic tests (87%) were obtained from retrospectively identified stored samples. Forty-eight percent of the genotypic tests obtained retrospectively were from plasma samples specifically selected for this analysis. All samples were collected at the EuroSIDA clinical sites and underwent a quality assessment. NOTE. ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; IDU, injection drug use; IS, interpretation system; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted PI; t0 and t1, first and second genotypic resistance tests in a pair; TAM1, TAM profile 1; TAM2, TAM profile 2.
a Adjusted for age, sex, calendar date of t0, viral load at t0, CD4 count at t0, time on TA-based regimens from virological failure to t1, HIV subtype, TA included in regimen, number of failed drugs before t0, lamivudine in failing regimen at t0, detection of 184IV at t0, and switch of у1 drug besides TA during t0-t1.
Statistical analysis. In a subset of patients in whom a GRT had been performed during the 3 months preceding the date of estimated virological failure, we calculated a crude estimate of the rate of TAM accumulation as the number of TAMs that were detected at baseline-t0, but not at the prefailure GRT, divided by the person-years of follow-up (PYFUs) between the tests.
In the main analysis, with the baseline the date of first GRT in a pair (t0), the statistical unit was pairs of GRTs, and patients with j GRTs ( ) contributed pairs (eg, a patient with j у 2 j Ϫ 1 2 eligible genotype tests contributed 1 pair, a patient with 3 eligible genotype tests contributed 2 pairs, etc). Therefore, by definition, not all statistical units in our analysis were independent of each other (correlation being higher between pairs of GRTs coming from the same individuals).
Patients' characteristics at t0 were described, and average (mean or median) changes in laboratory markers from t0 to t1 were evaluated using simple regression and multilevel modeling accounting for nonindependence of observations (with similar results). In this analysis, it was assumed that TAMs identified at t0 were still present at t1. The rate of TAM accumulation was calculated as the number of TAMs detected at t1 that had not been detected at t0, divided by the time between t0 and t1 (expressed as a rate per PYFU). Analyses were repeated in patients with a set number of TAMs (ie, 0-3, 4-5) detected at first GRT and in other subsets grouped according to the type of ART received at t0.
A multivariable Poisson regression model was performed to identify independent predictors of TAM accumulation. All predictors known or thought to be potentially associated with the risk of accumulation of resistance were included in a single multivariable model showing mutually adjusted relative rates. The full list of predictors included in the multivariable model is shown in Table 1 . To account properly for the fact that a patient could contribute 11 pair of genotypes, a generalized estimating equation model was fitted with first-order autoregressive working correlation structures (results were robust to the choice of this working matrix) using Proc Genmod in SAS Statistical Analysis Software, version 9 (http://www.sas.com/) [17] . The model assumes a constant rate of resistance accumulation over time; this hypothesis was validated by comparing 6-month incidence rates (data not shown). NOTE.Versions 6.4.1 and 7.1 were used for the Rega interpretation system (IS), and version 17 for the Agence Nationale de Recherches sur le SIDA (ANRS) system. SD, standard deviation; t0 and t1, first and second genotypic resistance tests in a pair. ABC, abacavir; AZT, zidovudine; ddI, didanosine; NNRTI, nonnucleoside reverse-transcriptase inhibitor; 3TC, lamivudine; TDF, tenofovir.
We also simulated a hypothetical situation in which all patients studied, at the end of the prolonged period in which they were kept on a TA-based ART regimen with a viral load of 1500 copies/mL, would be switched to specific virtual nucleoside pairs currently considered by the WHO as candidates for use in second-line regimens in RLSs (eg, zidovudine plus didanosine or abacavir plus didanosine) ( Table 2) ; as a result of the TAM accumulation during t0-t1, these regimens are pre- dicted to have diminished activity at t1. The Rega IS, and the Agence Nationale de Recherches sur le SIDA [ANRS] system in a sensitivity analysis [18] , were used to derive predicted susceptibility at both t0 and t1. The difference in predicted activity between t0 and t1 was calculated, averaged, standardized per interval between t0 and t1, and used as a measure of the decrease in susceptibility due to accumulation of resistance.
RESULTS
Patient characteristics.
We included 339 patients who contributed 603 pairs of GRTs: 227 with 1 pair (67%), 62 with 2 (18%), 20 with 3 (6%), and 30 (9%) with 13 pairs (Table 3 ). The characteristics of the patients studied (Table 3) were similar to those of EuroSIDA patients who experienced virological failure while receiving a TA but who did not satisfy the inclusion criteria for this analysis (median age, 39 years; 23% were female; 45% were men who have sex with men; viral load and CD4 count at time of failure).
Laboratory markers. At t0, the median viral load was 4.11 log 10 copies/mL (interquartile range [IQR], 3.53-4.72 log 10 copies/mL) and the median CD4 count was 244 cells/mL (IQR, 147-375 cells/mL). There was a median of 3 viral load measurements (IQR, 2-5) between t0 and t1. In 87 patients with a viral load measured before any ART was initiated, the median viral load suppression below this value at t0 was 0.75 log 10 copies/mL (IQR, 0.27-1.26 log 10 copies/mL) ( Table 4 ). In this same subset of patients, the median increase in the CD4 cell count compared with the pre-ART level was 116 cells/mL (IQR, 25-270 cells/mL). During the interval t0-t1 (median, 6 months; range, 1-89 months) we observed very stable viral loads (mean absolute change, +0.03 log 10 copies/mL; 95% confidence interval [CI], Ϫ0.03 to +0.09; t test for difference from 0, P p ) and CD4 counts (mean absolute change, Ϫ5.74 cells/mL; .29 95% CI, Ϫ2.52 to +14.00;
). The estimated average P p .17 monthly viral load and CD4 cell count changes did not vary according to the type of ART received at t0 (data not shown). Patients who experienced virological failure while receiving a TA but who did not satisfy the inclusion criteria for this analysis showed a significantly steeper annual increase in viral load (0.10 log 10 copies/mL/year; ). P ! .001 Antiretroviral drugs. Patients were receiving a zidovudinecontaining regimen for 176 pairs (29%) and a stavudine-containing regimen for 427 pairs (Table 4) . At the first GRT in a pair, the median number of drugs in regimen was 3 (range, 2-6), and the type of regimen received (all included either zidovudine or stavudine) was a triple-nucleoside combination ( 9%] ). Overall, there was a high rate of switches in the drugs besides the TA between t0 and t1, with 478 pairs (79%) in which у1 drug that was used at t0 was no longer used at t1, or vice versa.
HIV drug resistance. The median number of TAMs at t0 was 3 (range, 0-6), counting 41L, 67N, 70R, 210W, 215FY, and 219EQ only; in a univariable linear regression model, the mean number of TAMs at t0 was correlated with the time since virological failure of the TA (new TAMs, 0.11 per year since the estimated date of virological failure; 95% CI, 0.05-0.18 new TAMs per year;
). Table 5 shows the detailed distri-P ! .001 bution of drug resistance detected in major virus populations at t0 and the estimated proportions of pairs with mutations at t1, with the assumption of indefinite persistence of mutations Time between tests (t0-t1), median (range), months 6 (1-89) Viral load suppression below pre-ART level at t0, median (range), log 10 copies/mL (n p 87) 0.75 (Ϫ2.44 to +3.30) CD4 increase above pre-ART level at t0, median (range), cells/mL (n p 87) +116 (Ϫ550 to +312) Viral load at t0, median (range), log 10 copies/mL 4. detected at t0 at any time after t0. The rate of accumulation of TAM profile 1 (TAM1) mutations was 12-fold faster than that of TAM profile 2 (TAM2) mutations (which was mainly driven by 67N).
Rate of accumulation of resistance. In 139 patients with a GRT before the estimated date of virological failure with TA, we observed 28 TAMs during 136 PYFUs for a rate of accumulation of 0.20 per year (95% CI, 0.14-0.28 per year). In the main analysis, during the period of prospective observation t0-t1, 126 more TAMs were accumulated during 548 PYFUs with a similar estimated rate (0.23 per year; 95% CI, 0.20-0.27 per year); the corresponding rates were 0.30 per year (95% CI, 0.25-0.35 per year) in the subset of 330 pairs with 0-3 TAMs at t0 (106 new TAMs during 351 PYFUs) and 0.26 per year (95% CI, 0.14-0.41 per year) in the subset of 132 pairs for which only 1 viral load was seen by clinicians between t0 and t1 (12 new TAMs during 46 PYFUs). In 245 patients who already had 4-5 TAMs at t0, a slower rate was observed: 0.11 per year (20 new TAMs during 179 PYFUs). Crude rates were similar after stratification by type of ART received at t0 (data not shown). Table 2 shows the crude estimate of the mean predicted reduction in susceptibility of WHO candidate nucleoside pairs for second-line regimens in RLSs caused by accumulation of resistance during t0-t1. The mean Rega IS-predicted susceptibility of 1.08 for the pair zidovudine-tenofovir suggests that, on average, the activity of this combination at t0 was already reduced by almost one-half as a result of the mutations detected at that point. The right-hand column in Table 2 shows the estimate of the mean reduction in susceptibility per year based on the reduction during t0-t1 (eg, 0.09 per year for zidovudinetenofovir). As shown in previous analyses, the ANRS predictions for nucleosides tend to be more conservative than Rega predictions because of the smaller number of mutations involved in the rules [19] . Nevertheless, both systems seem to consistently indicate that nucleoside pairs including tenofovir (especially when used with lamivudine) were likely to have the 
NOTE.
Values represent numbers (percentages) of genotypic resistance test (GRT) pairs in which a mutation was detected at the first (t0) or second (t1) test in the pair, unless otherwise indicated. Total numbers of thymidine analogue mutations (TAMs) and crude rates for accumulation of single mutations are also shown. CI, confidence interval; IAS-USA, International AIDS Society-USA; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; PYFUs, person-years of followup; TAM1, TAM profile 1; TAM2, TAM profile 2.
a Rates for single mutations (or patterns of mutations) were calculated for subsets of pairs in which the specific mutation was not detected at t0. The rates of accumulation of 184IV NNRTI and PI resistance were not estimated, because patients were not necessarily kept on a lamivudine regimen, NNRTI, or PI for the duration of t0-t1.
greatest activity at t0 and the smallest reduction in activity due to accumulation of resistance during t0-t1.
Predictors of TAM accumulation. Table 6 shows faster rates of accumulation associated with greater predicted activity of the drugs received (ie, lower level of resistance detected) at t0. In the adjusted analysis including all 603 pairs (Table 1) , the rate of accumulation of TAMs was confirmed to be 12-fold faster ( ) in patients whose virus was predicted by the P ! .001 IS to be susceptible to the TA, compared with those whose virus was predicted to be resistant. Furthermore, a greater susceptibility to the other drugs included in the failing regimen besides the TA was associated with faster accumulation of TAMs (50% faster per additional active drug received at t0; ) (Table P p .02 1). Results were consistent when the ANRS predictions were used (data not shown) and when the analysis was restricted to patients with 0-3 TAMs at t0 (Table 1) .
The only other factors that consistently showed a significant association with faster accumulation of TAMs were acquisition of HIV infection through heterosexual contacts (compared with homosexual contacts, there was a ∼2-fold difference in rates;
) and the detection of TAM2 profiles at t0 (compared P p .05 with TAM1 profiles, 87% faster;
). The use at t0 of both P p .03 NNRTI and PI versus NNRTI-based therapies was associated with a slower rate of accumulation (relative rate, 0.32; P p ) ( Table 1) . .02
DISCUSSION
Our analysis indicates that patients who are kept on a virologically failing regimen containing a TA acquire new TAMs at a relatively slow rate (on average, 1 additional TAM every 4.3 years of exposure to the regimen). The rate of acquisition of NOTE. Versions 6.4.1 and 7.1 were used for the Rega interpretation system (IS), and version 17 for the Agence Nationale de Recherches sur le SIDA (ANRS) system. CI, confidence interval; GRT, genotypic resistance test; PYFUs, person-years of follow-up; t0 and t1, first and second GRTs in a pair.
у1 TAM in the subset of pairs in which 0-3 TAMs were detected at t0 was similar (1 per 3.3 years, but with a large CI ranging between 1 per 2.9 and 1 per 4 years). TAM1 mutations seemed to accumulate at a rate that was twice as fast as TAM2 mutations.
At baseline-t0, a median of 12 months after virological failure with a TA, an appreciable TA-associated resistance could already be detected: an average of 3 TAMs, with mutations 41L or 215Y detected in 65%-70% of patients and 67N in 52%. A crude analysis of the rate of TAM accumulation between a GRT performed before the occurrence of virological failure and the first GRT in a pair yielded an estimate similar to that observed during t0-t1, suggesting that TAMs accumulate in a linear fashion, at least during the first 1.5 years after virological failure.
Patients with the fastest rate of TAM accumulation were those who had the highest predicted activity of the failing regimen at t0. For the TA component of the regimen, this is equivalent to saying that those with fewer TAMs had a greater likelihood of accumulating more TAMs (although even in those with a virus predicted to be susceptible to TA, the accumulation was still slow, at 1 TAM per 2.7 years) ( Table 6 ). Reasons for the associations with the susceptibility to the non-TA component of the regimen are unclear, but they may be related to patients' level of adherence to ART. To exclude patients who might be completely nonadherent, we restricted the analysis to those for whom there was evidence of resistance to the regimen used at t0. However, full adjustment for adherence levels could not be performed, because data on adherence are collected only in a small subset of patients in EuroSIDA, producing very few data that could be compared with these estimates.
In one study, у29 new TAMs were detected in 41 episodes of failing therapy during an average of 110 weeks (rate, 0.31 per year; 95% CI, 0.22-0.42 per year), only slightly higher than our estimate, which is included in their CI [12] . In their study population of patients (for whom 12 TAMs were detected and clinical notes indicated 175% adherence to medication supplied), the authors found that the accumulation of TAMs was slower in patients who continued to receive a lamivudine-containing regimen, whereas there was no association between the use of lamivudine and the rate of TAM accumulation in our analysis. In addition, we found no association between the detection of 184IV at t0 and the rate of TAM accumulation (with or without concomitant adjustment for the use of lamivudine; data not shown). In agreement with the results of previous analyses, there was no difference in the rates of TAM accumulation between patients who received zidovudine and those who received stavudine [12, 20] . Of note, the accumulation of mutation 70E was observed for only 1 pair, and there was no accumulation of mutation 65R; therefore, we were not able to determine whether the accumulation rate for these mutations might have been lower with the use of zidovudine, as shown in other studies [15, 16] . Another estimation of the rate of accumulation of TAMs comes from a small study of 10 patients with !2 TAMs detected at failure and у2 accumulated TAMs during a mean of 103 weeks (estimated rate, 2 per 22 PYFUs, or 0.09 per year; 95% CI, 0.01-0.29), consistent with our estimate [21] . Other studies that investigated accumulation of mutations on longitudinal samples obtained while patients were on the same regimens did not provide specific estimates for TAM accumulation [22, 23] and often did not provide a breakdown of the exposure to single drugs, so that a direct comparison is not possible [23] .
In the study by Kantor et al [22] , it appears that ∼36 mutations at positions 41, 67, 70, 210, 215, and 219 of reverse transcriptase had accumulated in 106 patients followed up for an average of 14 months (0.29 TAMs per year; 95% CI, 0.21-0.38 TAMs per year), again in line with our estimates.
Before conclusions are drawn, a few limitations of this analysis should be discussed. First, it is not possible from our data to establish the most likely reason that patients in EuroSIDA were kept on virologically failing regimens (these may include waiting for genotypic test results, lack of available options, and patients' choices), so selection bias cannot be ruled out. There was no difference in sociodemographic characteristics between our study population and patients who experienced virological failure while receiving TA but did not satisfy the inclusion criteria for this analysis, but as anticipated, a steeper annual viral load increase was seen in the latter group than in the patients included in our analysis (0.10 log 10 copies/mL per year vs 0.03 log 10 copies/mL per year;
). Therefore, our es-P ! .001 timated rates of resistance accumulation may not apply to the average patients experiencing failure of a TA-containing regimen in EuroSIDA. However, when we restricted our analysis to GRT pairs with only 1 viral load measurement between them, so that the reason for not switching was less likely to be due to slow viral load increase, the estimated rate of TAM accumulation was consistent with that found in the main analysis. Second, although there was variability in what subjects received other than zidovudine-stavudine, our results are adjusted for the number of drugs predicted to be active in addition to the TA and according to whether drugs were switched between t0 and t1.
Only 9% of our patients ( ) had non-B subtypes, and n p 31 24% were receiving ART currently recommended by the WHO as suitable for first-line regimens. Therefore, our results may not be fully generalized to the context of patients in resourcelimited countries. However, the similarity between our estimate of the rate at which resistance accumulates and that observed in RLS studies suggests that this bias may be negligible [9] . Finally, because standard genotyping can detect only mutations that are well represented in major populations, we cannot rule out that mutations defined in our analysis as "newly detected at t1" could be already present at t0 but not detected in the majority virus. Conversely, on average, 20%-30% of mutations that were detected at t0 and assumed to still be present at t1 could not be detected by the test at t1 (data not shown). This could partly explain the observed association between a faster rate of TAM "accumulation" and a lower level of resistance at t0 and, more generally, could lead to overestimation of the real rate of TAM accumulation.
In conclusion, our data suggest that, in patients who continue to receive TA-based, virologically failing regimens, the rate of accumulation of TAMs is relatively slow, on average, though the higher the activity of the regimen, the faster the rate at which TAMs accumulate. Nucleoside pairs including tenofovir, although expensive, seem more likely to be active against viruses harboring TAMs and also to experience the lowest drop in activity in the face of TAM accumulation. Additional research in this area is needed to inform program planning in RLSs.
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